Cardeas Pharma Secures $34,000,000 Series B Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a0230868-49b2-44cb-a0e1-564866a064c0&Preview=1 - Date
5/23/2013 - Company Name
Cardeas Pharma - Mailing Address
2025 First Avenue Seattle, WA 98121 - Company Description
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. - Website
http://www.cardeaspharma.com - Transaction Type
Venture Equity - Transaction Amount
$34,000,000 - Transaction Round
Series B - Proceeds Purposes
Funds from this financing will be used to support Phase 2 development of Cardeas’ lead compound, investigational amikacin/fosfomycin inhalation solution delivered via an eFlow InLine Nebulizer system, as a potential treatment for healthcare associated pneumonia (HCAP) in patients on mechanical ventilation. - M&A Terms
- Venture Investor
H.I.G. Capital - Venture Investor
Novo Ventures - Venture Investor
Avalon Ventures - Venture Investor
WRF Capital - Venture Investor
De Novo Ventures - Venture Investor
Devon Park Bioventures
